Global pioneers of convenient treatment for allergy and immune related disorders.
Transforming lives by delivering convience.
As a Healthcare professional, you understand the importance of convenience in allergy treatments, because this allows you to deliver the best patient care.
We are a visionary immunology business with specialist experience in the research and development of allergy treatments.
Work with us.
Meta-analysis of primary endpoint of PQ Grass 27600 SU field studies with optimized dose and treatment regimen of PQ Grass 27600 SU
Secondary endpoint profile is strongly supportive for the positive outcome of the pivotal Phase III study with PQ Grass 27600 SU
Positive outcome of the pivotal Phase III study with PQ Grass 27600 SU, a modified grass allergen subcutaneous immunotherapy (SCIT) product using MicroCrystalline Tyrosine and Monophosphoryl Lipid A as adjuvant system
Hypoallergenic Safety Profile of a Novel Virus-like Particle Vaccine for the Treatment of Peanut Allergy supported by Skin Prick Testing
Peripheral blood mononuclear cell transcriptome profile in a clinical trial with subcutaneous, grass pollen allergoid immunotherapy
